isoxazoles has been researched along with tivozanib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bichat, F; Fujiwara, Y; Guilbaud, N; Hasegawa, K; Isae, T; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Suzuki, R; Taguchi, E; Takahashi, K; Yamamoto, A | 1 |
| Isoe, T; Miura, T; Nakamura, K; Shibuya, M; Taguchi, E | 1 |
2 other study(ies) available for isoxazoles and tivozanib
| Article | Year |
|---|---|
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Endothelial Cells; Humans; Isoxazoles; Magnetic Resonance Imaging; Mice; Neoplasms; Neovascularization, Pathologic; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
Topics: Animals; Antineoplastic Agents; Ascites; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Humans; Isoxazoles; Neovascularization, Pathologic; Peritoneal Neoplasms; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred F344; Receptors, Vascular Endothelial Growth Factor | 2008 |